drugset / Trial / NCT02586129

Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes

NCT02586129

Phase 3 Completed 249 enrolled Yuhan Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

Randomized, double-blind, active-controlled, multicenter phase 3 trial to evaluate the safety and efficacy of YH14755 in subjects with dyslipidemia and Type II Diabetes.

Timeline

Start
2015-11-04
Primary completion
2017-07-07
Completion
2017-07-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Metformin Small molecule 1500 mg Oral
Comparator Rosuvastatin Small molecule 20 mg Oral
Subject YH14755 Unknown Oral